High materiality8/10
Ultragenyx Pharma (RARE) PT Raised to $39 at Cantor Fitzgerald on FAYUVI Approval
Why it may matterVerify against the original reporting
bullish
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Cantor Fitzgerald raises RARE PT to $39; current price 14.50; approval cited as upside catalyst.
- PT $39; price $14.50; approval catalyzes upside.
Key facts
- 01
Target: $39
- 02
Posted price: $14.5
- 03
Analyst firm: Cantor Fitzgerald
- 04
Analyst: Kristen Kluska
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.